Healthcare Industry News: CoreValve
News Release - August 28, 2009
Stentys appoints Vice President of Sales and MarketingFormer Johnson & Johnson executive Paul Geudens joins Stentys on the heels of CE Mark approval
“The hiring of Paul Geudens underscores our aggressive commercialization plans for the European market.” -- Gonzague Issenmann, co-founder and CEO of Stentys
PRINCETON, N.J. & PARIS--(HSMN NewsFeed)--Medical device pioneer Stentys, which has designed a new-generation stent platform for treatment of (1) acute myocardial infarction (AMI) and (2) coronary artery bifurcations, announced today that it has appointed interventional cardiology veteran Paul Geudens as Vice President of Sales & Marketing, effective immediately.
Mr. Geudens was previously employed for the past 11 years at Cordis Corp. (Johnson & Johnson), most recently as Director of Marketing, Peripheral and Neurovascular Products, where he led new product launches across the franchise.
“Paul knows the cath lab market as well as anyone,” said Gonzague Issenmann, Stentys’ co-founder and CEO. “He was the head of the interventional cardiology department at University Hospital Antwerp at the start of his professional career, and combined with his extensive business experience over more than two decades, Paul is an outstanding addition to our management team.”
“Paul joins Stentys on the heels of the Company’s CE Mark approval for its disconnectable and self-expanding platform, and he will lead Stentys’ commercial development in this $2.5 billion market,” added Jacques Séguin, M.D., Ph.D., co-founder and Chairman of Stentys and founder of CoreValve.
Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. Stentys was co-founded by Gonzague Issenmann and Jacques Séguin, M.D., Ph.D., founder of CoreValve, which was acquired this year by Medtronic for $700 million plus earn-outs.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.